Health care workers in the Deaconess emergency department now have a new way to treat patients with opioid withdrawal symptoms: long-acting injectable buprenorphine.

Medically reviewed by Melissa Bronstein, LICSW Key Takeaways Withdrawal happens when a person stops or reduces intake of an ...

A deeper understanding of the communication inside the body when someone is going through opioid withdrawal has led to a new clinical trial at the University of Calgary. I don't think I've had a day ...

Lofexidine is administered during the period of peak withdrawal symptoms. The Food and Drug Administration (FDA) has approved Lofexidine Tablets 0.18mg, the first generic of Lucemyra. Lofexidine is a ...

Opioid use and abuse is a significant social, health and economic issue in Canada. Researchers at the University of Calgary's Faculty of Veterinary Medicine (UCVM) and Hotchkiss Brain Institute (HBI) ...

We’re fighting yesterday’s war while innocent patients pay the price.

Low-dose opioid therapy provides stable, long-term symptom control and dose stability for patients with augmented restless legs syndrome.

However, the opioid pathway, a heavily studied physiologic pathway inextricably intertwined with behaviour and reward, rarely receives attention within psychiatric practice. Although the opioid system ...

An existing drug currently used to treat glaucoma, altitude sickness, and seizures may also have the potential to prevent ...

An existing drug currently used to treat glaucoma, altitude sickness, and seizures may also have potential for preventing relapse in opioid use disorder, according to a new study by researchers at ...